AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-1 receptor type 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P14778

UPID:

IL1R1_HUMAN

Alternative names:

CD121 antigen-like family member A; Interleukin-1 receptor alpha; Interleukin-1 receptor type I; p80

Alternative UPACC:

P14778; Q587I7

Background:

Interleukin-1 receptor type 1 (IL-1R1), encoded by the gene P14778, serves as a critical component in the immune response pathway. It acts as a receptor for interleukins IL1A, IL1B, and IL1RN, facilitating the formation of a high-affinity receptor complex with IL1RAP. This complex is pivotal in activating NF-kappa-B, MAPK, and other signaling pathways, essential for the immune response and inflammation regulation. IL-1R1's ability to bind ligands with comparable affinity and its role in IL1B-mediated costimulation of IFNG production from Th1 cells underscore its significance in immune modulation.

Therapeutic significance:

Understanding the role of Interleukin-1 receptor type 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.